Neil H. Shusterman

8.3k total citations · 1 hit paper
35 papers, 5.1k citations indexed

About

Neil H. Shusterman is a scholar working on Cardiology and Cardiovascular Medicine, Nephrology and Surgery. According to data from OpenAlex, Neil H. Shusterman has authored 35 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Cardiology and Cardiovascular Medicine, 12 papers in Nephrology and 6 papers in Surgery. Recurrent topics in Neil H. Shusterman's work include Heart Failure Treatment and Management (8 papers), Dialysis and Renal Disease Management (7 papers) and Blood Pressure and Hypertension Studies (6 papers). Neil H. Shusterman is often cited by papers focused on Heart Failure Treatment and Management (8 papers), Dialysis and Renal Disease Management (7 papers) and Blood Pressure and Hypertension Studies (6 papers). Neil H. Shusterman collaborates with scholars based in United States, South Korea and Norway. Neil H. Shusterman's co-authors include Wilson S. Colucci, Milton Packer, Jay N. Cohn, Edward M. Gilbert, Michael B. Fowler, Michael R. Bristow, Brian L. Strom, Gail Morrison, Greg Maislin and Thomas G. Murray and has published in prestigious journals such as New England Journal of Medicine, Circulation and Annals of Internal Medicine.

In The Last Decade

Neil H. Shusterman

33 papers receiving 4.8k citations

Hit Papers

The Effect of Carvedilol on Morbidity and Mortality in Pa... 1996 2026 2006 2016 1996 1000 2.0k 3.0k

Peers

Neil H. Shusterman
Livio Dei Italy
Neil H. Shusterman
Citations per year, relative to Neil H. Shusterman Neil H. Shusterman (= 1×) peers Livio Dei

Countries citing papers authored by Neil H. Shusterman

Since Specialization
Citations

This map shows the geographic impact of Neil H. Shusterman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neil H. Shusterman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neil H. Shusterman more than expected).

Fields of papers citing papers by Neil H. Shusterman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neil H. Shusterman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neil H. Shusterman. The network helps show where Neil H. Shusterman may publish in the future.

Co-authorship network of co-authors of Neil H. Shusterman

This figure shows the co-authorship network connecting the top 25 collaborators of Neil H. Shusterman. A scholar is included among the top collaborators of Neil H. Shusterman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neil H. Shusterman. Neil H. Shusterman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shusterman, Neil H., et al.. (2013). Current Topics in Opioid Therapy for Pain Management: Addressing the Problem of Abuse. Clinical Drug Investigation. 33(7). 459–468. 6 indexed citations
2.
Shusterman, Neil H.. (2002). Risk-benefit assessment of angiotensin II receptor antagonists. Expert Opinion on Drug Safety. 1(2). 137–152. 3 indexed citations
3.
Tendera, Michał, Andrew J.S. Coats, Michael B. Fowler, et al.. (2002). Effect of gender on the outcome of patients with severe heart failure treated with carvedliol: results of the COPERNICUS study. Journal of the American College of Cardiology. 39. 185–185. 1 indexed citations
4.
Joglar, José A., Neil H. Shusterman, Karthik Ramaswamy, et al.. (2001). Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: Retrospective analysis of the US Carvedilol Heart Failure Trials Program. American Heart Journal. 142(3). 498–501. 106 indexed citations
5.
Wang, Andrew, Terry L. Holcslaw, Thomas M. Bashore, et al.. (2000). Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. Kidney International. 57(4). 1675–1680. 159 indexed citations
6.
Holmes, David R., Peter J. Fitzgerald, Sheldon Goldberg, et al.. (2000). The PRESTO (Prevention of Restenosis with Tranilast and its Outcomes) protocol: A double-blind, placebo-controlled trial. American Heart Journal. 139(1). 23–31. 63 indexed citations
7.
Eichhorn, Eric J., et al.. (2000). Effect of concomitant digoxin and carvedilol therapy on mortality and morbidity in patients with chronic heart failure. The American Journal of Cardiology. 86(9). 1032–1035. 25 indexed citations
8.
Stone, Richard A., et al.. (1998). Fenoldopam, A Selective Dopamine-1 Receptor Agonist, Raises Intraocular Pressure in Males with Normal Intraocular Pressure. Journal of Ocular Pharmacology and Therapeutics. 14(3). 203–216. 12 indexed citations
9.
Krum, Henry, Neil H. Shusterman, Stephen MacMahon, & Norman Sharpe. (1998). Efficacy and safety of carvedilol in patients with chronic heart failure receiving concomitant amiodarone therapy. Journal of Cardiac Failure. 4(4). 281–288. 15 indexed citations
10.
Fowler, Michael B., Edward M. Gilbert, Jay N. Cohn, et al.. (1996). Effects of carvedilol on cardiovascular hospitalizations in patients with chronic heart failure. Journal of the American College of Cardiology. 27(2). 169–169. 8 indexed citations
11.
Packer, Milton, Michael R. Bristow, Jay N. Cohn, et al.. (1996). The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure. New England Journal of Medicine. 334(21). 1349–1355. 3406 indexed citations breakdown →
12.
Shusterman, Neil H., et al.. (1996). The De Novo Diagnosis of Systemic Lupus Erythematosus in a Hemodialysis Patient. JCR Journal of Clinical Rheumatology. 2(3). 160–162. 3 indexed citations
13.
Packer, Milton, Wilson S. Colucci, Jonathan Sackner‐Bernstein, et al.. (1996). Double-Blind, Placebo-Controlled Study of the Effects of Carvedilol in Patients With Moderate to Severe Heart Failure. Circulation. 94(11). 2793–2799. 458 indexed citations
14.
Shusterman, Neil H., et al.. (1992). Illness in hemodialysis patients after exposure to chloramine contaminated dialysate.. PubMed. 37(4). 588–91. 25 indexed citations
15.
Ilson, Bernard E., Diane K. Jorkasky, Neil H. Shusterman, et al.. (1992). Intraoperative versus Routine Hemodialysis in End-Stage Renal Disease Patients Undergoing Open-Heart Surgery. ˜The œNephron journals/Nephron journals. 61(2). 170–175. 7 indexed citations
16.
Jorkasky, Diane K., et al.. (1992). Fenoldopam Reverses Cyclosporine-Induced Renal Vasoconstriction in Kidney Transplant Recipients. American Journal of Kidney Diseases. 19(6). 567–572. 31 indexed citations
17.
Shusterman, Neil H., et al.. (1989). Successful use of double-lumen, silicone rubber catheters for permanent hemodialysis access. Kidney International. 35(3). 887–890. 80 indexed citations
18.
Shusterman, Neil H., et al.. (1989). Reprocessing of Hemodialyzers: A Critical Appraisal. American Journal of Kidney Diseases. 14(2). 81–91. 17 indexed citations
19.
Berman, Claudia G., MICHAEL G. VELCHIK, Neil H. Shusterman, & Abass Alavi. (1989). The Clinical Utility of the Tc-99m SC Intraperitoneal Scan in CAPD Patients. Clinical Nuclear Medicine. 14(6). 405–409. 9 indexed citations
20.
Shusterman, Neil H.. (1985). Factors Influencing Erythrocyte Sedimentation in Patients With Chronic Renal Failure. Archives of Internal Medicine. 145(10). 1796–1796. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026